# Leveraging the causal effects of stochastic interventions to evaluate vaccine efficacy in two-phase trials

Nima Hejazi

Wednesday, 16 December 2020

Graduate Group in Biostatistics, and Center for Computational Biology, University of California, Berkeley



nhejazi

**i** nimahejazi.org

with , D. Benkeser, M. van der Laan, H. Janes, P. Gilbert SER: "Methods for the thorny challenges of real studies"



#### The burden of HIV-1

- The HIV-1 epidemic the facts:
  - now in its fourth decade,
  - 2.5 million new infections occurring annually worldwide,
  - new infections outpace patients starting antiretroviral therapy.
- Most efficacious preventive vaccine: 31% reduction rate.
- Question: To what extent can HIV-1 vaccines be improved by modulating immunogenic CD4+/CD8+ response profiles?

### HVTN 505 trial examined new antibody boost vaccines

- HIV Vaccine Trials Network's (HVTN) 505 vaccine efficacy;
   randomized controlled trial, n = 2504 (Hammer et al. 2013).
- Question: How would HIV-1 infection risk in week 28 have changed had immunogenic response (due to vaccine) differed?
- Immunogenic response profiles only available for second-stage sample of n=189 (Janes et al. 2017) due to cost limitations.
- Two-phased sampling mechanism: 100% inclusion rate if HIV-1 positive in week 28; based on matching otherwise.

- Baseline covariates(L): sex, age, BMI, behavioral HIV risk.
- Intervention(s) (A): post-vaccination T-cell activity markers.
- Outcome (*Y*): HIV-1 infection status at week 28 of tiral.
- 12-color intracellular cytokine staining (ICS) assay.
   Cryopreserved peripheral blood mononuclear cells were stimulated
- with synthetic HIV-1 peptide pools.
  All immune responses are assayed after the endpoints of interest
- Conclusion: Understanding which immune responses impact

vaccine efficacy helps develop more efficacious vaccines.

(HIV-1 infection status) are collected.

 A vaccine effective at preventing HIV-1 acquisition would be a cost-effective and durable approach to halting the worldwide epidemic.

### Two-phase sampling censors the complete data structure

- Complete (<u>unobserved</u>) data  $X = (L, A, Y) \sim P_0^X \in \mathcal{M}^X$ , as per the full HVTN 505 trial cohort (Hammer et al. 2013):
  - L (baseline covariates): sex, age, BMI, behavioral HIV risk,
  - A (exposure): immune response profile for CD4+ and CD8+,
  - Y (outcome of interest): HIV-1 infection status at week 28.
- Observed data O = (C, CX) = (L, C, CA, Y);  $C \in \{0, 1\}$  is an indicator for inclusion in the second-stage sample.

- $P_0^X$  true (unknown) distribution of the full data X,
- $\mathcal{M}_{NP}^{X}$  nonparametric statistical model.

#### **NPSEM** with static interventions

 Use a nonparametric structural equation model (NPSEM) to describe the generation of X (Pearl 2009), specifically

$$L = f_L(U_L); A = f_A(L, U_A); Y = f_Y(A, L, U_Y)$$

- Implies a model for the distribution of counterfactual random variables generated by interventions on the process.
- A static intervention replaces f<sub>A</sub> with a specific value a in its conditional support A | L.
- This requires specifying a particular value of the exposure under which to evaluate the outcome a priori.

#### **NPSEM** with stochastic interventions

- Stochastic interventions modify the value A would naturally assume by drawing from a modified exposure distribution.
- Consider the post-intervention value  $A^* \sim G^*(\cdot \mid L)$ ; static interventions are a special case (degenerate distribution).
- Such an intervention generates a counterfactual random variable  $Y_{G^*} := f_Y(A^*, L, U_Y)$ , with distribution  $P_0^{\delta}$ , .
- We aim to estimate  $\psi_{0,\delta} := \mathbb{E}_{P_0^\delta}\{Y_{G^\star}\}$ , the counterfactual mean under the post-intervention exposure distribution  $G^\star$ .

#### Stochastic interventions for the causal effects of shifts

Díaz and van der Laan (2012; 2018)'s stochastic interventions

$$d(a, l) = \begin{cases} a + \delta, & a + \delta < u(l) & \text{(if plausible)} \\ a, & a + \delta \ge u(l) & \text{(otherwise)} \end{cases}$$

- Our estimand is  $\psi_{0,d} := \mathbb{E}_{P_0^d} \{ Y_{d(A,L)} \}$ , mean of  $Y_{d(A,L)}$ .
- Statistical target parameter is  $\Psi(P_0^X) = \mathbb{E}_{P_0^X} \overline{Q}(d(A, L), L)$ , counterfactual mean of the *shifted* outcome mechanism.
- For HVTN 505,  $\psi_{0,d}$  is the counterfactual risk of HIV-1 infection, had the observed value of the immune response been altered under the rule d(A, L) defining  $G^*(\cdot \mid L)$ .

• Causal estimand: counterfactual mean of HIV-1 infection (risk) under a *shifted* immunogenic response distribution.

#### Flexible, efficient estimation

The efficient influence function (EIF) is:

$$D(P_0^X)(x) = H(a, l)(y - \overline{Q}(a, l)) + \overline{Q}(d(a, l), l) - \Psi(P_0^X).$$

 The one-step estimator corrects bias by adding the empirical mean of the estimated EIF to the substitution estimator:

$$\Psi_n^+ = \frac{1}{n} \sum_{i=1}^n \overline{Q}_n(d(A_i, L_i), L_i) + D_n(O_i).$$

 The TML estimator is built by updating initial estimates of \overline{Q}\_n via a (logistic) tilting model, yielding

$$\Psi_n^{\star} = \frac{1}{n} \sum_{i=1}^n \overline{Q}_n^{\star}(d(A_i, L_i), L_i).$$

 Both estimators are CAN even when nuisance parameters are estimated via flexible, machine learning techniques.

- Semiparametric-efficient estimation thru solving efficient influence function estimating equation wrt the model  $\mathcal{M}$ .
- The auxiliary covariate simplifies when the treatment is in the limits (conditional on W) — i.e., for  $A_i \in (u(I) - \delta, u(I))$ , then we have  $H(a, l) = \frac{g_0(a-\delta|l)}{g_0(a|l)} + 1.$ 
  - Need to explicitly remind the audience what u(I) is again. It's only
  - appeared once at this point, and only been mentioned in passing.

## Augmented estimators for two-phase sampling designs

- Rose and van der Laan (2011) introduce the IPCW-TMLE, to be used when observed data is subject to two-phase sampling.
- Initial proposal: correct for two-phase sampling by using a loss function with inverse probability of censoring weights:

$$\mathcal{L}(P_0^X)(O) = \frac{C}{\pi_0(Y, L)} \mathcal{L}^F(P_0^X)(X)$$

- When the sampling mechanism  $\pi_0(Y, L)$  can be estimated by a parametric form, this procedure yields an efficient estimator.
- However, when machine learning is used (e.g., when  $\pi_0(Y, L)$  is not *known by design*), this is insufficient.

### Efficient estimation and multiple robustness

Then, the IPCW augmentation must be applied to the EIF:

$$D(P_0^X)(o) = \frac{c}{\pi_0(y, l)} D^F(P_0^X)(x) - \left(1 - \frac{c}{\pi_0(y, l)}\right) \cdot \mathbb{E}(D^F(P_0^X)(x) \mid C = 1, Y = y, L = l),$$

- Expresses observed data EIF  $D^F(P_0^X)(o)$  in terms of full data EIF  $D^F(P_0^X)(x)$ ; inclusion of second term ensures efficiency.
- The expectation of the full data EIF  $D^F(P_0^X)(x)$ , taken only over units selected by the sampling mechanism (i.e., C=1).
- A unique multiple robustness property combinations of  $(g_0(L), \overline{Q}_0(A, L)) \times (\pi_0(Y, L), \mathbb{E}(D^F(P_0^X)(x) \mid C = 1, Y, L)).$

### Helping to fight the HIV-1 epidemic




Figure 1: Analysis of HIV-1 risk as a function of CD8+ immunogenicity, using R package txshift (https://github.com/nhejazi/txshift.)

### Big picture takeaways

- Vaccine efficacy evaluation helps to develop enhanced vaccines better informed by biological properties of the target disease.
- HIV-1 vaccines modulate immunogenic response profiles as part of their mechanism for lowering HIV-1 infection risk.
- Stochastic interventions constitute a flexible framework for considering realistic treatment/intervention policies.
- Large-scale (vaccine) trials often use two-phase designs —
   need to (carefully!) accommodate for sampling complications.
- We've developed robust, open source statistical software for assessing stochastic interventions in observational studies.

## Thank you!

- ♣ https://nimahejazi.org
- Ohttps://github.com/nhejazi
- https://doi.org/10.1111/biom.13375

Appendix

## From the causal to the statistical target parameter

### **Assumption 1:** *Consistency*

$$Y_i^{d(a_i,l_i)} = Y_i$$
 in the event  $A_i = d(a_i,l_i)$ , for  $i = 1, \ldots, n$ 

#### **Assumption 2: SUTVA**

$$Y_i^{d(a_i,l_i)}$$
 does not depend on  $d(a_j,l_j)$  for  $i=1,\ldots,n$  and  $j\neq i$ , or lack of interference (Rubin 1978; 1980)

## Assumption 3: Strong ignorability

$$A_i \perp Y_i^{d(a_i,l_i)} \mid L_i$$
, for  $i = 1, \ldots, n$ 

## From the causal to the statistical target parameter

## Assumption 4: Positivity (or overlap)

 $a_i \in \mathcal{A} \implies d(a_i, l_i) \in \mathcal{A}$  for all  $l \in \mathcal{L}$ , where  $\mathcal{A}$  denotes the support of A conditional on  $L = l_i$  for all i = 1, ... n

- This positivity assumption is not quite the same as that required for categorical interventions.
- In particular, we do not require that the intervention density place mass across all strata defined by L.
- Rather, we merely require the post-intervention quantity be seen in the observed data for given  $a_i \in A$  and  $l_i \in \mathcal{L}$ .

## Literature: Díaz and van der Laan (2012)

- Proposal: Evaluate outcome under an altered intervention distribution e.g.,  $P_{\delta}(g_0)(A = a \mid L) = g_0(a \delta(L) \mid L)$ .
- Identification conditions for a statistical parameter of the counterfactual outcome  $\psi_{0,d}$  under such an intervention.
- Show that the causal quantity of interest  $\mathbb{E}_0\{Y_{d(A,L)}\}$  is identified by a functional of the distribution of X:

$$\psi_{0,d} = \int_{\mathcal{L}} \int_{\mathcal{A}} \mathbb{E}_{P_0^X} \{ Y \mid A = d(a, l), L = l \} \cdot$$
$$q_{0,A}^X(a \mid L = l) \cdot q_{0,L}^X(l) d\mu(a) d\nu(l)$$

 Provides a derivation based on the efficient influence function (EIF) with respect to the nonparametric model M.

- The identification result allows us to write down the causal quantity of interest in terms of a functional of the observed data.
   Key innovation: loosening standard assumptions through a change
- in the observed intervention mechanism.
- Problem: globally altering an intervention mechanism does not necessarily respect individual characteristics.
- The authors build IPW, A-IPW, and TML estimators, comparing the three different approaches.
- IMPORTANT: gives the g-computation formula for identification of this estimator from the observed data structure.

## Literature: Haneuse and Rotnitzky (2013)

- Proposal: Characterization of stochastic interventions as modified treatment policies (MTPs).
- Assumption of piecewise smooth invertibility allows for the intervention distribution of any MTP to be recovered:

$$g_{0,\delta}(a \mid I) = \sum_{j=1}^{J(I)} I_{\delta,j}\{h_j(a,I),I\}g_0\{h_j(a,I) \mid I\}h_j'(a,I)$$

- Such intervention policies account for the natural value of the intervention A directly yet are interpretable as the imposition of an altered intervention mechanism.
- Identification conditions for assessing the parameter of interest under such interventions appear technically complex (at first).

- Shifts of the form d(A, L) are considerably more interesting since these are realistic intervention policies.
- Example: consider an individual with an extremely high immune response but whose baseline covariates L suggest we shift the response still higher. Such a shift may not be biologically plausible
- response still higher. Such a shift may not be biologically plausible (impossible, even) but we cannot account for this if the shift is only a function of L.
- The authors build IPW, outcome regression, and non-iterative doubly robust estimators, as well as an approach based on MSMs.
- Piecewise smooth invertibility: This assumption ensures that we can use the change of variable formula when computing integrals over A and it is useful to study the estimators that we propose in this paper.

## Literature: Young et al. (2014)

- Establishes equivalence between g-formula when proposed intervention depends on natural value and when it does not.
- This equivalence leads to a sufficient positivity condition for estimating the counterfactual mean under MTPs via the same statistical functional studied in Díaz and van der Laan (2012).
- Extends earlier identification results, providing a way to use the same statistical functional to assess  $\mathbb{E}Y_{d(A,L)}$  or  $\mathbb{E}Y_{d(L)}$ .
- The authors also consider limits on implementing shifts d(A, L), and address working in a longitudinal setting.

## Literature: Díaz and van der Laan (2018)

- Builds on the original proposal, accommodating MTP-type shifts d(A, L) proposed after their earlier work.
- To protect against positivity violations, considers a specific shifting mechanism:

$$d(a, l) = \begin{cases} a + \delta, & a + \delta < u(l) \\ a, & \text{otherwise} \end{cases}$$

- Proposes an improved "1-TMLE" algorithm, with a single auxiliary covariate for constructing the TML estimator.
- Our (first) contribution: implementation of this algorithm.

#### Nonparametric conditional density estimation

- To compute the auxiliary covariate H(a, l), we need to estimate conditional densities  $g(A \mid L)$  and  $g(A \delta \mid L)$ .
- There is a rich literature on density estimation, we follow the approach proposed in Díaz and van der Laan (2011).
- To build a conditional density estimator, consider

$$g_{n,\alpha}(a \mid L) = \frac{\mathbb{P}(A \in [\alpha_{t-1}, \alpha_t) \mid L)}{\alpha_t - \alpha_{t-1}},$$

for  $\alpha_{t-1} \leq a < \alpha_t$ .

- This is a classification problem, where we estimate the probability that a value of A falls in a bin  $[\alpha_{t-1}, \alpha_t)$ .
- The choice of the tuning parameter *t* corresponds roughly to the choice of bandwidth in classical kernel density estimation.

#### Nonparametric conditional density estimation

- Díaz and van der Laan (2011) propose a re-formulation of this classification approach as a set of hazard regressions.
- To effectively employ this proposed re-formulation, consider

$$\mathbb{P}(A \in [\alpha_{t-1}, \alpha_t) \mid L) = \mathbb{P}(A \in [\alpha_{t-1}, \alpha_t) \mid A \ge \alpha_{t-1}, L) \times$$
$$\Pi_{j=1}^{t-1} \{ 1 - \mathbb{P}(A \in [\alpha_{j-1}, \alpha_j) \mid A \ge \alpha_{j-1}, L) \}$$

- The likelihood of this model may be expressed to correspond to the likelihood of a binary variable in a data set expressed via a long-form repeated measures structure.
- Specifically, the observation of  $X_i$  is repeated as many times as intervals  $[\alpha_{t-1}, \alpha_t)$  are before the interval to which  $A_i$  belongs, and the binary variables indicating  $A_i \in [\alpha_{t-1}, \alpha_t)$  are recorded.

## Density estimation with the Super Learner algorithm

- To estimate  $g(A \mid L)$  and  $g(A \delta \mid L)$ , use a pooled hazard regression, spanning the support of A.
- We rely on the Super Learner algorithm of van der Laan et al. (2007) to build an ensemble learner that optimally weights each of the proposed regressions, using cross-validation (CV).
- The Super Learner algorithm uses V-fold CV to train each proposed regression model, weighting each by the inverse of its average risk across all V holdout sets.
- By using a library of regression estimators, we invoke the result of van der Laan et al. (2004), who prove this likelihood-based cross-validated estimator to be asymptotically optimal.

- The auxiliary covariate simplifies when the treatment is in the limits (conditional on L) i.e., for  $A_i \in (u(I) \delta, u(I))$ , then we have  $H(a, I) = \frac{g_0(a \delta | I)}{g_0(a | I)} + 1$ .
- Asymptotically optimal in the sense that it performs as well as the oracle selector as the sample size increases.

## Key properties of TML estimators

Asymptotic linearity:

$$\Psi(P_n^*) - \Psi(P_0^X) = \frac{1}{n} \sum_{i=1}^n D(P_0^X)(X_i) + o_P\left(\frac{1}{\sqrt{n}}\right)$$

Gaussian limiting distribution:

$$\sqrt{\textit{n}}(\Psi(\textit{P}^{\star}_\textit{n}) - \Psi(\textit{P}^{X}_\textit{0})) \rightarrow \textit{N}(0, \textit{Var}(\textit{D}(\textit{P}^{X}_\textit{0})(\textit{X})))$$

Statistical inference:

Wald-type confidence interval : 
$$\Psi(P_n^{\star}) \pm z_{1-\frac{\alpha}{2}} \cdot \frac{\sigma_n}{\sqrt{n}}$$
,

where  $\sigma_n^2$  is computed directly via  $\sigma_n^2 = \frac{1}{n} \sum_{i=1}^n D^2(\cdot)(X_i)$ .

Under the additional condition that the remainder term  $R(\hat{P}^{\star}, P_0)$  decays as  $o_P\left(\frac{1}{\sqrt{n}}\right)$ , we have that  $\Psi_n - \Psi_0 = (P_n - P_0) \cdot D(P_0) + o_P\left(\frac{1}{\sqrt{n}}\right)$ , which, by a central limit theorem, establishes a Gaussian limiting distribution for the estimator, with variance  $V(D(P_0))$ , the variance of the efficient influence function when  $\Psi$  admits an asymptotically linear representation.

The above implies that  $\Psi_n$  is a  $\sqrt{n}$ -consistent estimator of  $\Psi$ , that it is asymptotically normal (as given above), and that it is locally efficient. This allows us to build Wald-type confidence intervals, where  $\sigma_n^2$  is an estimator of  $V(D(P_0))$ . The estimator  $\sigma_n^2$  may be obtained using the bootstrap or computed directly via  $\sigma_n^2 = \frac{1}{n} \sum_{i=1}^n D^2(\bar{Q}_n^{\star}, g_n)(O_i)$ We obtain semiparametric-efficient estimation and robust inference in the

nonparametric model  ${\mathcal M}$  by solving the efficient influence function.

- 1. If  $D(\bar{Q}_n^*, g_n)$  converges to  $D(P_0)$  in  $L_2(P_0)$  norm.
- 2. The size of the class of functions  $\bar{Q}_n^*$  and  $g_n$  is bounded (technically,  $\exists \mathcal{F} \text{ st } D(\bar{Q}_n^*, g_n) \in \mathcal{F} \text{ whp, where } \mathcal{F} \text{ is a Donsker class})$

## Algorithm for TML estimation

- 1. Construct initial estimators  $g_n$  of  $g_0(A, L)$  and  $Q_n$  of  $\overline{Q}_0(A, L)$ , perhaps using data-adaptive regression techniques.
- 2. For each observation i, compute an estimate  $H_n(a_i, l_i)$  of the auxiliary covariate  $H(a_i, l_i)$ .
- 3. Estimate the parameter  $\epsilon$  in the logistic regression model

$$\operatorname{logit} \overline{Q}_{\epsilon,n}(a,l) = \operatorname{logit} \overline{Q}_n(a,l) + \epsilon H_n(a,l),$$

or an alternative regression model incorporating weights.

4. Compute TML estimator  $\Psi_n$  of the target parameter, defining update  $\overline{Q}_n^{\star}$  of the initial estimate  $\overline{Q}_{n,\epsilon_n}$ :

$$\Psi_n = \Psi(P_n^*) = \frac{1}{n} \sum_{i=1}^n \overline{Q}_n^*(d(A_i, L_i), L_i).$$

- We recommend using nonparametric methods for the initial estimators, as consistent estimation is necessary for efficiency of the estimator  $\Psi_n$ .
- Intuition for the submodel fluctuation?

# **Algorithm for IPCW-TML estimation**

- 1. Using all observed units (X), estimate sampling mechanism  $\pi(Y, L)$ , perhaps using data-adaptive regression methods.
- 2. Using only observed units in the second-stage sample C=1, construct initial estimators  $g_n(A,L)$  and  $\overline{Q}_n(A,L)$ , weighting by the sampling mechanism estimate  $\pi_n(Y,L)$ .
- 3. With the approach described for the full data case, compute  $H_n(a_i, l_i)$ , and fluctuate submodel via logistic regression.
- 4. Compute IPCW-TML estimator  $\Psi_n$  of the target parameter, by solving the IPCW-augmented EIF estimating equation.
- 5. Iteratively update estimated sampling weights  $\pi_n(Y, L)$  and IPCW-augmented EIF, updating TML estimate in each iteration, until  $\frac{1}{n} \sum_{i=1}^n \mathsf{EIF}_i < \frac{1}{n}$ .

- We recommend using nonparametric methods for the initial estimators, as consistent estimation is necessary for efficiency of the estimator  $\Psi_n$ .
- Intuition for the submodel fluctuation?
  - This process includes the use of HAL to fit the regression of the EIF contributions on the sampling node { Y, L}.

### Identifying the best efficient estimator




Figure 2: Relative performance of reweighted and augmented estimators.

### A linear modeling perspective

- Briefly consider a simple data structure: X = (Y, A); we seek to model the outcome Y as a function of A.
- To posit a linear model, consider  $Y_i = \beta_0 + \beta_1 A_i + \epsilon_i$ , with error  $\epsilon_i \sim N(0,1)$ .
- Letting  $\delta$  be a change in A,  $Y_{A+\delta} Y_A$  may be expressed

$$\mathbb{E}Y_{A+\delta} - \mathbb{E}Y_A = [\beta_0 + \beta_1(\mathbb{E}A + \delta)] - [\beta_0 + \beta_1(\mathbb{E}A)]$$
$$= \beta_0 - \beta_0 + \beta_1\mathbb{E}A - \beta_1\mathbb{E}A + \beta_1\delta$$
$$= \beta_1\delta$$

• Thus, a *unit shift* in A (i.e.,  $\delta=1$ ) may be seen as inducing a change in the difference in outcomes of magnitude  $\beta_1$ .

- We extend this result to the mean counterfactual outcomes under the nonparametric model M.
- Linear modeling analogy re: conversation with Alan on 22 August.

## A causal inference perspective

- Consider a data structure:  $(Y_a, a \in A)$ .
- To posit a linear model, let  $Y_a = \beta_0 + \beta_1 a + \epsilon_a$  for  $a \in \mathcal{A}$ , with error  $\epsilon_a \sim N(0, \sigma_a^2) \ \forall a \in \mathcal{A}$ .
- For the counterfactual outcomes  $(Y_{a'+\delta}, Y_{a'})$ , their difference,  $Y_{a'+\delta} Y_{a'}$ , for some  $a' \in \mathcal{A}$ , may be expressed

$$\mathbb{E}Y_{a'+\delta} - \mathbb{E}Y_{a'} = [\beta_0 + \beta_1(a'+\delta) + \mathbb{E}\epsilon_{a'+\delta}] - [\beta_0 + \beta_1a' + \mathbb{E}\epsilon_{a'}]$$
$$= \beta_1\delta$$

• Thus, a *unit shift* for  $a' \in A$  (i.e.,  $\delta = 1$ ) may be seen as inducing a change in the difference in the counterfactual outcomes of magnitude  $\beta_1$ .

- Note that this analysis is exactly what we're told we cannot do in linear models 101 — that is, the slope of a regression line cannot be interpreted as causing a change in the outcome.
- We extend this result to the mean counterfactual outcomes under the nonparametric model  $\mathcal{M}.$
- Linear modeling analogy re: conversation with Alan on 22 August.
- Example updated to incorporate countercatuals re: conversation with David on 30 August

### Slope in a semiparametric model

• Consider the stochastic intervention  $g^*(\cdot \mid L)$ :

$$\mathbb{E}Y_{g^*} = \int_L \int_a \mathbb{E}(Y \mid A = a, L)g(a - \delta \mid L) \cdot da \cdot dP_0(L)$$
$$= \int_L \int_z \mathbb{E}(Y \mid A = z + \delta, L)g(z \mid L) \cdot dz \cdot dP_0(L),$$

defining the change of variable  $z = a - \delta$ .

For a semiparametric model,  $\mathbb{E}(Y \mid A = z, L) = \beta z + \theta(L)$ :

$$\mathbb{E}Y_{g^*} - \mathbb{E}Y = \int_{L} \int_{z} \left[ \mathbb{E}(Y \mid A = z + \delta, L) - \mathbb{E}(Y \mid A = z, L) \right]$$
$$g(z \mid L) \cdot dz \cdot dP_{0}(L)$$
$$= \left[ \beta(z + \delta) + \theta(L) \right] - \left[ \beta z + \theta(L) \right]$$
$$= \beta \delta$$

#### References

- Breiman, L. (1996). Stacked regressions. *Machine Learning*, 24(1):49–64.
- Díaz, I. and van der Laan, M. J. (2011). Super learner based conditional density estimation with application to marginal structural models. *The international journal of biostatistics*, 7(1):1–20.
- Díaz, I. and van der Laan, M. J. (2012). Population intervention causal effects based on stochastic interventions. *Biometrics*, 68(2):541–549.
- Díaz, I. and van der Laan, M. J. (2018). Stochastic treatment regimes. In Targeted Learning in Data Science: Causal Inference for Complex Longitudinal Studies, pages 167–180. Springer Science & Business Media.
- Dudoit, S. and van der Laan, M. J. (2005). Asymptotics of cross-validated risk estimation in estimator selection and performance assessment. *Statistical Methodology*, 2(2):131–154.

- Hammer, S. M., Sobieszczyk, M. E., Janes, H., Karuna, S. T., Mulligan, M. J., Grove, D., Koblin, B. A., Buchbinder, S. P., Keefer, M. C., Tomaras, G. D., et al. (2013). Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. New England Journal of Medicine, 369(22):2083–2092.
- Haneuse, S. and Rotnitzky, A. (2013). Estimation of the effect of interventions that modify the received treatment. *Statistics in medicine*, 32(30):5260–5277.
- Holland, P. W. (1986). Statistics and causal inference. *Journal of the American statistical Association*, 81(396):945–960.
- Janes, H. E., Cohen, K. W., Frahm, N., De Rosa, S. C., Sanchez, B., Hural, J., Magaret, C. A., Karuna, S., Bentley, C., Gottardo, R., et al. (2017). Higher t-cell responses induced by dna/rad5 hiv-1 preventive vaccine are associated with lower hiv-1 infection risk in an efficacy trial. *The Journal of infectious diseases*, 215(9):1376–1385.

- Kennedy, E. H. (2018). Nonparametric causal effects based on incremental propensity score interventions. *Journal of the American Statistical Association*, (just-accepted).
- Kennedy, E. H., Ma, Z., McHugh, M. D., and Small, D. S. (2017). Non-parametric methods for doubly robust estimation of continuous treatment effects. *Journal of the Royal Statistical Society: Series B* (Statistical Methodology), 79(4):1229–1245.
- Pearl, J. (2009). *Causality: Models, Reasoning, and Inference*. Cambridge University Press.
- Rose, S. and van der Laan, M. J. (2011). A targeted maximum likelihood estimator for two-stage designs. *The International Journal of Biostatistics*, 7(1):1–21.
- Rosenbaum, P. R. and Rubin, D. B. (1983). The central role of the propensity score in observational studies for causal effects. Biometrika, 70(1):41-55.

- Rubin, D. B. (1978). Bayesian inference for causal effects: The role of randomization. *The Annals of statistics*, pages 34–58.
- Rubin, D. B. (1980). Randomization analysis of experimental data: The fisher randomization test comment. *Journal of the American Statistical Association*, 75(371):591–593.
- Rubin, D. B. (2005). Causal inference using potential outcomes: Design, modeling, decisions. *Journal of the American Statistical Association*, 100(469):322–331.
- optimality of likelihood-based cross-validation. *Statistical Applications in Genetics and Molecular Biology*, 3(1):1–23. van der Laan, M. J., Polley, E. C., and Hubbard, A. E. (2007). Super

van der Laan, M. J., Dudoit, S., and Keles, S. (2004). Asymptotic

- Learner. Statistical Applications in Genetics and Molecular Biology, 6(1).
- van der Laan, M. J. and Rubin, D. (2006). Targeted maximum likelihood learning. *The International Journal of Biostatistics*, 2(1).

Wolpert, D. H. (1992). Stacked generalization. Neural networks, 5(2):241-259.

Young, J. G., Hernán, M. A., and Robins, J. M. (2014). Identification, estimation and approximation of risk under interventions that depend on the natural value of treatment using observational data.

Epidemiologic methods, 3(1):1-19.